Supplementary Tables 1 from Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study
- James W. Smithy
- , Hannah L. Kalvin
- , Fiona D. Ehrich
- , Ronak Shah
- , Matthew Adamow
- , Vladislav Raber
- , Collen A. Maher
- , Jenna Kleman
- , Deborah A.G. McIntyre
- , Alexander N. Shoushtari
- , Allison Betof Warner
- , Margaret K. Callahan
- , Parisa Momtaz
- , Omar Eton
- , Suresh Nair
- , Jedd D. Wolchok
- , Paul B. Chapman
- , Michael F. Berger
- , Katherine S. Panageas
- , Michael A. Postow
No endorsements
This article has not been endorsed yet.
Like this work?
Let others know. Sign in to add your endorsement.